FR2903009A1 - Cosmetic and/or dermatological composition comprises useful e.g. to treat skin pathologies related to abnormal exfoliation, such as the xerosis, ichtyosis, psoriasis, atopic dermatitis, a desquamating agent and a C-glycoside derivative - Google Patents

Abstract

Cosmetic and/or dermatological composition comprises a desquamating agent (0.001-95 wt.%) and a C-glycoside derivative (I), in a medium. Independent claims are included for: (1) a process of cosmetic treatment for the non-therapeutic care of the skin and/or scalp, comprising simultaneous or sequential application of (I) and a desquamating agent on the skin, through a composition; and (2) cosmetic treatment of the visible and/or tactile irregularities of the human skin, comprising: topically applying the cosmetic composition to the skin, leaving the composition in contact with the skin for 5 minutes to 6 hours, preferably 5-30 minutes and eliminating the composition by rinsing. ACTIVITY : Dermatological; Antipsoriatic. MECHANISM OF ACTION : None given.

Description

The present invention relates to a cosmetic composition and / or

  Dermatological useful in particular for promoting desquamation of the skin and / or scalp and / or stimulating epidermal renewal, comprising the combination of at least one desquamating agent in a content ranging from 0.001 to 95% by weight relative to the weight total of the composition and at least one C-glycoside derivative.  It may especially be a care composition and / or make-up of the materials and / or keratin fibers.  Within the meaning of the invention, the term "keratin materials and / or fibers" is intended to denote, for example, the skin, the mucous membranes, the scalp, the eyelashes, the eyebrows and the hair.  By skin, we mean in the broad sense the skin and semi-mucous membranes (lips).  Flaking is a natural phenomenon due to the fact that the epidermis, which constitutes the upper layer of the skin and the scalp, is in constant regeneration.  The epidermis consists of several layers of cells, the deepest of which is the basal layer of undifferentiated cells.  Over time, these cells will differentiate and migrate to the surface of the epidermis by constituting the different bases of it, to form on the surface of the epidermis corneocytes which are dead cells that eliminate by desquamation.  This loss of surface is compensated by the migration of cells from the basal layer to the surface of the epidermis.  It is the perpetual renewal of the skin.  Forced removal of the stratum corneum accelerates the renewal and helps to fight against aging.  At the same time these cells continue their differentiation whose last stage is the corneocyte.  It is in fact dead cells which constitute the last layer of the epidermis, ie the outermost layer, also called stratum, slowing epidermal renewal and consequently an aging of the skin, and / or thickening of the stratum corneum (ex: formation of callosities), and / or desquamative disorders of aesthetic type (eg dandruff, dander. . . ) or pathological (eg xerosis, ichthyosis, psoriasis, atopic dermatitis).  corneum.  It is known that the desquamation process can be altered by exogenous factors (eg UV radiation, pollution, allergenic agents, pathogens), and / or endogenous (ex: hormonal changes, age. . . ) In particular with regard to cutaneous aging, resulting from intrinsic or extrinsic factors, it generally results in the appearance of wrinkles and fine lines, by the yellowing of the skin which develops a parchment-like appearance accompanied by the appearance of pigment spots, by the disorganization of the elastin and collagen fibers resulting in a loss of elasticity, flexibility and firmness or by the appearance of telangiectasia.  Some of these signs of aging are more particularly related to intrinsic or physiological aging, that is to say age-related "normal" or chronobiological aging, while others are more specific to extrinsic aging. that is to say aging generally caused by the environment; this is particularly photoaging due to exposure to the sun, light or other radiation.  Skin changes due to intrinsic aging are the result of genetically programmed senescence involving endogenous factors.  This intrinsic aging notably causes a slowing down of the renewal of the cells of the skin, which essentially results in the appearance of clinical alterations such as the reduction of the subcutaneous adipose tissue and the appearance of fine lines or wrinkles, and by histopathological changes such as an increase in the number and thickness of the elastic fibers, a loss of vertical fibers of the elastic tissue membrane, and the presence of large irregular fibroblasts in the cells of this elastic tissue.  In contrast, extrinsic aging results in clinical alterations such as thick wrinkles and soft, tanned skin formation, and histopathological changes such as excessive build-up of elastic material in the upper dermis and degeneration of the skin fibers. collagen.  The invention is particularly interested in intrinsic or physiological aging as well as extrinsic aging.  Various agents are known in the prior art for combating skin aging, among which are antioxidants, agents promoting the proliferation and / or differentiation of dermal and / or epidermal cells, agents stimulating the expression of macromolecules. dermal or epidermal, as many 2903009 3 agents as cellular or molecular targets in the skin to prevent and / or reduce the multiple effects of skin aging.  Thus, US Pat. No. 4,603,146 describes the use of retinoic acid and its derivatives in cosmetic compositions, with a view to combating skin aging. .  In addition to these agents intended to combat skin aging, desquamating agents are also added.  In general, desquamating agents act by facilitating the removal of dead cells located on the surface of the stratum corneum of the epidermis.  This "desquamating" property is also called, often erroneously, keratolytic property.  Unfortunately, certain desquamating compounds may, when used in high concentrations, also have side effects such as cutaneous discomfort.  There is therefore a need to find alternative solutions for example by finding ways to use said desquamating agents at lower doses to reduce these side effects.  The inventors have surprisingly discovered that certain C-glycoside derivatives make it possible to enhance the desquamating action of desquamating agents.  C-glycoside derivatives are described in particular in WO 02/051828 for their properties on the synthesis of glycosaminoglycans (GAGs) and in particular for improving the hydration and the suppleness of the skin.  Thus, according to one of its aspects, the invention relates to a cosmetic and / or dermatological composition comprising in a physiologically acceptable medium: from 0.001 to 95% by weight relative to the total weight of the composition of at least one desquamating agent and, at least one C-glycoside derivative.  According to another of its aspects, the subject of the invention is the cosmetic use of at least one desquamating agent in combination with at least one C-glycoside derivative or a composition according to the invention for promoting desquamation of the skin and / or the scalp and / or stimulate epidermal renewal, and in particular to prevent, attenuate and / or fight against the signs of skin aging, improve the appearance and / or the texture of the skin and / or the scalp, and in particular to improve the radiance and homogeneity of the complexion and / or to smooth the skin, to reduce the surface irregularities and the cutaneous microrelief, to promote the cleaning action and the elimination of dead cells on the surface of the body, to promote the elimination of dandruff, to fight against the imperfections of oily skin, to improve the hold of makeup and / or to improve the treatment result of the skin with stratum corneum dyes such as dihydroxyacetone (DHA).  The invention also relates to the use of at least one desquamating agent in combination with at least one C-glycoside derivative or a composition according to the invention for the preparation of a composition intended to treat certain skin-related pathologies. abnormal desquamation, such as xerosis, ichthyosis, psoriasis, atopic dermatitis.  The subject of the invention is also a cosmetic treatment method for the non-therapeutic care of the skin and / or the scalp, characterized in that it comprises applying simultaneously or sequentially to the skin, via at least one composition, at least one C-glycoside derivative and at least one desquamating agent.  The cosmetic treatment method according to the invention may comprise at least one step of applying to the skin and / or the scalp a cosmetic composition according to the present invention.  The cosmetic treatment method for the non-therapeutic care of the skin and / or the scalp according to the invention is more particularly a method for promoting desquamation of the skin and / or scalp, and / or stimulating epidermal renewal. , and in particular to prevent, attenuate and / or fight against the signs of skin aging, improve the appearance and / or texture of the skin and / or the scalp, and in particular improve the radiance and homogeneity of the complexion and / or smooth the skin, reduce surface irregularities and cutaneous microrelief, promote the cleaning action and the removal of dead cells on the surface of the body, promote the elimination of dandruff, improve the makeup hold and / or improve the skin treatment result with stratum corneum dyes such as dihydroxyacetone (DHA).  In the process according to the invention, the C-glycoside derivative and the desquamating agent may be packaged in two separate compositions.  The improvement in the hold of makeup and / or skin coloring treatments with DHA results from the fact that the skin and / or the scalp can be prepared before the makeup and / or the aforementioned coloration (s). ) by the application of a composition according to the invention, which will promote the result of a simultaneous or subsequent treatment with a makeup agent or a coloring agent.  By "sign of skin aging" is meant all changes in the external appearance of the skin and / or its texture due to chronological or photoinduced aging such as, for example, wrinkles, fine lines, wilted skin, soft skin, thinned skin, lack of elasticity or tone of the skin.  The pro-desquamating activity is actually sought mainly in the field of so-called anti-aging compositions, namely intended to fight against cutaneous signs due to aging and / or photoaging.  However, the combination used according to the present invention may also find applications in the attenuation of surface irregularities of the skin and the improvement of the cutaneous microrelief, in particular the attenuation of actinic lentigo, acne marks or chicken pox, unclogging the pores of the skin; the treatment of dry skin, and oily and acne-prone skin.  For oily skin, it is often associated with a lack of desquamation, and a thick skin texture.  In addition, the excess of sebum can serve as a support for the anarchic development of the saprophytic bacterial flora (in particular Propionibacterium acnes and Pityrosporum ovale), and to cause comedones and / or acne lesions.  These acne lesions constitute another cutaneous sign of oily skin which can advantageously be combatted by employing at least one composition according to the present invention.  In the context of the present invention, it is meant that all the aforementioned conditions are covered under the term "improve the appearance and / or texture of the skin and / or scalp", as well as in the more particular term " to improve the radiance and homogeneity of the complexion and / or to improve the cutaneous microrelief ".  For the implementation of this method, the combination of a desquamating agent and a C-glycoside derivative or the composition according to the invention may be applied to any area of the skin or its appendages, in particular the face, décolleté, hands, or on the lips, to reduce the visible and / or tactile irregularities of the skin, for example to reduce scarring, to smooth the surface and / or eliminate dead skin including lips.  According to a particular embodiment, the C-glycoside derivative and the desquamating agent which are the objects of the combination according to the invention may be packaged in two separate compositions and applied simultaneously or sequentially.  By way of example, the composition comprising C-glycoside can be applied to prepare the skin for subsequent application of the desquamating agent.  In addition, many cutaneous pathologies are characterized by the production of a thickened horny layer and by abnormal desquamation, that is to say by hyperkeratosis.  This can occur on any anatomical skin and in a wide variety of clinical contexts.  Its pathophysiological substratum and its cause are varied.  Advantageously, the combination and the compositions in accordance with the invention make it possible to promote desquamation of the skin and / or to stimulate epidermal renewal and therefore more particularly to treat the cutaneous and / or scalp pathologies which are characterized by the production thickened horny layer and / or abnormal desquamation.  Consequently, the present invention also relates, according to another of its aspects, to the use of the combination or a composition according to the invention for the preparation of a composition intended to treat cutaneous pathologies and / or leather which are characterized by the production of a thickened horny layer and / or abnormal desquamation.  By way of nonlimiting illustration of these cutaneous and / or scalp disorders related to a dysregulation of desquamation, mention may be made in the context of the present invention: xeroses - acne, hyperkeratosis, psoriasis, atopy and ichthyosis.  The combination of at least one desquamating agent and at least one C-glycoside derivative or a composition according to the invention makes it possible to promote the desquamation of the skin and / or the scalp and / or to stimulate epidermal renewal. and may therefore be used for the preparation of a dermatological composition for treating the aforementioned skin conditions which are characterized by the production of a thickened horny layer and / or abnormal desquamation.  Finally, the composition according to the present invention finds another application in the field of chemical peels.  The combination according to the invention is therefore advantageous in peeling compositions.  Peels are a well-known way to improve the appearance and / or texture of the skin and / or scalp, in particular to improve the radiance and homogeneity of the complexion and / or to reduce the visible and / or tactile irregularities of the skin and / or scalp. the skin, and in particular to improve the surface appearance of the skin, to reduce actinic lentigo, marks of acne or chickenpox, as well as to prevent, attenuate or fight against the signs of skin aging, and in particular to smooth out irregularities in the texture of the skin, such as wrinkles and fine lines.  They have the effect of removing a superficial part of the skin to be treated (epidermis and possibly superficial layer of the dermis) by chemical methods.  The subject of the invention is therefore a process for the cosmetic treatment of visible and / or tactile irregularities of human skin, comprising the steps of: a) applying a composition according to the present invention topically to the skin, b) leaving the composition in contact with the skin for a period of between 5 minutes and 6 hours, preferably between 5 minutes and 30 minutes, and c) remove the composition by rinsing.  According to an alternative embodiment, the invention relates to a cosmetic process for promoting desquamation of the skin and / or mucous membranes, comprising at least one step (i) of preparing the skin for peeling consisting of applying to areas to be treated at least one C-glycoside derivative as defined below, at least at a concentration below that leading to desquamation, and (ii) a subsequent step comprising applying at least one desquamating agent to a concentration adapted to cause desquamation.  A step of removing the desquamating agent (s) by rinsing will then be performed.  Advantageously, step (i) may be repeated with increasing concentrations of C-glycoside derivative.  These concentrations will be adapted by the skilled person according to the desired effect and the number of applications envisaged, but will generally be less than 10%.  For example, it is possible to use a first concentration of about 2%, then one or more successive applications with a concentration of about 4%, and then 6 or 8% by weight.  This method is more particularly intended to prevent, attenuate, and / or fight against the signs of skin aging, and in particular to reduce wrinkles and fine lines, and to improve the appearance and / or the texture of the skin, in particular to improve the homogeneity of the complexion and / or smooth the skin, and in particular attenuate actinic lentigo, or acne or chickenpox marks, and / or unclog the pores of the skin.  DEQUAMANT AGENT The term "desquamating agent" means any compound capable of acting: either directly on desquamation by promoting exfoliation, such as: saturated and unsaturated monocarboxylic acids, saturated and unsaturated dicarboxylic acids, acids saturated and unsaturated tricarboxylic; alpha hydroxy acids and beta hydroxy acids of monocarboxylic acids; alpha hydroxy acids and beta hydroxy acids of dicarboxylic acids; alpha hydroxy acids and beta hydroxy acids of tricarboxylic acids; ketoacids, alpha ketoacids, beta ketoacids of polycarboxylic acids, polyhydroxy monocarboxylic acids, polyhydroxybicarboxylic acids, polyhydroxy tricarboxylic acids; and (3-hydroxy-2-pentylcyclopentyl) acetic acid.  Preferred α-hydroxy acids include: glycolic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid.  The preferred 13-hydroxy acids are selected from: salicylic acid and its derivatives, in particular n-octanoyl-5-salicylic acid.  Other exfoliation agents that may be mentioned include: pyruvic acid, gluconic acid, glucuronic acid, oxalic acid, malonic acid, succinic acid, acetic acid, gentisic acid, cinnamic acid, azelaic acid; phenol, resorcinol; urea and its derivatives; oligofucoses as in patent EP 0 218 200; jasmonic acid and its derivatives as in patent applications EP 1 333 022 and EP 1 333 021; trichloroacetic acid; retinoids such as retinol, retinoic acid; adapalene; Saphora japonica extract; resveratrol; as well as their salts and derivatives, such as cis or trans forms, racemic mixtures, dextrorotatory or levogyrous forms of the aforementioned agents.  Or on the enzymes involved in the desquamation or the degradation of corneodesmosomes, such as glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like).  Mention may in particular be made of chelating agents for mineral salts such as EDTA; N-acyl-N, N ', N'-ethylene diaminetriacetic acid; aminosulfonic compounds and in particular (N-2 hydroxyethylpiperazine-N-2-ethane) sulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha amino acid derivatives (as described in EP 0 852 949, as well as sodium methyl glycine diacetate marketed by BASF under the trade name TRILON M); honey ; sugar derivatives such as O-octanoyl-6-D-maltose, O-linoleyl-6-D-glucose and N-acetyl glucosamine.  Other desquamating agents that can be used in the composition according to the invention include laminar extracts such as laminaria saccharina and laminaria ochrolenca, glycerol trilactate, and silicon salicylate derivatives, as in patent EP 0 796 861. 5-acyl salicylic acid salts, active agents having effects on transglutaminase as in EP 0 899 330, and a ficus opuntia indica flower extract as Exfolactivé de Silab.  Preferred desquamating agents include beta-hydroxy acids such as n-octanoyl-5-salicylic acid; urea and its derivatives; glycolic, citric, lactic, tartaric, malic or mandelic acids; (N-2-hydroxyethylpiperazine-N-2-ethane) sulfonic acid (HEPES); Saphora japonica extract; honey ; N-acetyl glucosamine; derivatives of 2-oxothiazolidine-4-carboxylic acid (procysteine) and mixtures thereof.  Even more preferably, in the composition of the invention, a desquamating agent chosen from glycolic acid, n-octanoyl-5-salicylic acid and (N-2-hydroxyethylpiperazine-N-2-ethane) acid will be used. sulfonic acid (HEPES), 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine) and mixtures thereof.  Those skilled in the art will be able to define the necessary amount of desquamating agent present in the combination according to the invention to obtain the desired effect on the skin.  By way of example, the desquamating agent may be in a content ranging from 0.001 to 95% by weight relative to the total weight of the composition, in particular from 0.01 to 30% by weight relative to the total weight of the composition. the composition, preferably from 0.01 to 10% by weight relative to the total weight of the composition.  When the composition has a peeling application, it may especially comprise from 0.01 to 90% by weight of desquamating agent (s) relative to the total weight of the composition, preferably from 1 to 70% by weight. relative to the total weight of the composition.  Preferably, in the peeling compositions at least 10% by weight and in particular more than 20% by weight, in particular from 21% to 50% by weight, and preferably from 21% to 30% by weight of desquamating agent relative to total weight of the composition.  C-GLYCOSIDE DERIVATIVES A C-glycoside derivative that is suitable for the invention may be a compound of the following general formula (I): embedded image wherein: R represents a linear C 1 to C 20 saturated alkyl radical; in particular C 1 to C 10, or unsaturated C 2 to C 20, in particular C 2 to C 10, or a branched or cyclic alkyl radical, saturated or unsaturated, C 3 to C 20, in particular C 3 to C 10: a hydrofluoro- or perfluoro radical; -alkyl, linear saturated C1 to C20, in particular C1 to C10, or unsaturated C2 to C20, in particular C2 to C10, or branched or cyclic, saturated or unsaturated, C3 to C20, in particular C3 to C20, C10; The hydrocarbon-based chain constituting said radicals can, if appropriate, be interrupted by 1 2, 3 or more heteroatoms chosen from: oxygen, a sulfur, a nitrogen, and a silicon, and which may optionally be substituted by at least one radical chosen from: -OR4, -SR4, -NR4R5, -COOR4, -CONHR4, -CN, a halogen atom, a C1-C6 hydrofluoro- or perfluoroalkyl radical, and / or a C3-C8 cycloalkyl radical, with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or an alkyl, perfluoroalkyl or linear hydrofluoroalkyl radical, saturated with C1 to C8, in particular C1 to C12, or unsaturated C2 to C30, especially C2 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, especially C3 to C12; or a C6 to C10 aryl radical, X represents a radical chosen from the groups: ## STR2 ## with R1, R2 and R3 representing, independently of one another, an atom of hydrogen, or a radical R, with R as defined above, and R '1 represents a hydrogen atom, a group OH or a radical R as defined above, RI may also denote a C6 to C10 aryl radical; S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, in particular up to 6 sugar units, in pyranose and / or furanose form, and of L and / or D series, said mono- or polysaccharide possibly being substituted by a necessarily free hydroxyl group, and optionally one or more optionally protected amine function (s), and the S-CH 2 -X bond represents a C-anomeric bond, which may be a or 0, as well as their cosmetically acceptable salts, their solvates such as hydrates and their isomers.  In the context of the present invention, halogen means chlorine, fluorine, bromine or iodine.  The term aryl designates an aromatic ring such as phenyl, optionally substituted with one or more C 1 -C 4 alkyl radicals.  The term C3-C8 cycloalkyl refers to an aliphatic ring having 3 to 8 carbon atoms, including, for example, cyclopropyl, cyclopentyl and cyclohexyl.  Among the alkyl groups which are suitable for the implementation of the invention, there may be mentioned in particular the methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl and pentyl groups. hexyl, cyclopropyl, cyclopentyl, cyclohexyl, and allyl.  According to one embodiment of the invention, it is possible to use a C-glycoside derivative corresponding to formula (I) for which S can represent a monosaccharide or a polysaccharide containing up to 6 sugar units, in pyranose and / or furanose and L and / or D series, said mono- or polysaccharide having at least one hydroxyl function necessarily free and / or optionally one or more functions amine 10 necessarily protected, X and R otherwise retaining all the definitions previously given.  Advantageously, a monosaccharide of the invention may be chosen from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L- rhamnose, D-glucuronic acid, D-galacturonic acid, D15 iduronic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and advantageously denotes D-glucose, D- xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose.  More particularly, a polysaccharide of the invention containing up to 6 sugar units may be selected from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide associating a uronic acid selected from D-iduronic acid or D-glucuronic acid with a hexosamine selected from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, an oligosaccharide containing at least a xylose which can be advantageously selected from among xylobiose, methyl-P-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and in particular xylobiose which is composed of two xylose molecules linked by a 1-4 bond.  More particularly, S may represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose and especially D-xylose.  According to another embodiment of the invention, it is possible to use C-glycoside derivatives corresponding to formula (I) for which X represents a group chosen from -CO-, -CH (OH) -, -CH (NR1R2 ) -, -CH (R) -, in particular -CO-, -CH (OH) -, 2903009 14 -CH (NH2) -, -CH (NHCH2CH2CH2OH) -, -CH (NHPh) -, -CH (CH3) and, more particularly, a group -CO-, -CH (OH) -, -CH (NH 2) -, and preferentially a group -CH (OH) -, S and R otherwise preserving all the definitions previously given.  According to another embodiment of the invention, it is possible to use a C-glycoside derivative corresponding to formula (I) for which R represents an alkyl radical in linear, saturated C1 to C20, in particular C1 to C10, or unsaturated C 2 to C 20, especially C 2 to C 10, or a branched or cyclic C 3 to C 20 saturated or unsaturated alkyl radical; in particular at C3 to C10, and optionally substituted as described above, S and R 10 furthermore preserving all the definitions previously given.  Preferably, R denotes a linear radical C1-C4, especially C1-C3, optionally substituted with OH, -COOH or COOR "2, R" 2 being a saturated alkyl radical C1-C4, especially ethyl.  Preferentially, R denotes an unsubstituted linear C1-C4, especially C1-C2, alkyl radical, in particular ethyl.  Among the C-glycoside derivatives of formula (I), use is preferably made of those for which: R represents a linear, saturated C 1 to C 20, in particular C 1 to C 10, or unsaturated C 2 to C 20 alkyl radical, in particular C 2 to C 10, or a branched or cyclic, saturated or unsaturated C 3 to C 20 alkyl radical; in particular C3 to C10, and optionally substituted as described above; S represents a monosaccharide as previously described; X represents -CO-, -CH (OH) -, -CH (NR1R2) -, -CH (R) - as previously described.  Preferably, a C-glycoside derivative of formula (I) is used, for which: R denotes a linear C1-C4, in particular C1-C3, radical optionally substituted by OH, -COOH or -COOR "2, R" 2; being a saturated C1-C4 alkyl radical, especially ethyl; S represents a monosaccharide as previously described; X represents a group chosen from -CO-, -CH (OH) -, -CH (NH2) -, -CH (NHCH2CH2CH2OH) -, -CH (NHPh) -, -CH (CH3) -, and more particularly a group -CO-, -CH (OH) -, -CH (NH2) -, and preferably a group -CH (OH) -.  Preferably, a C-glycoside derivative of formula (I) is used for which: R denotes an unsubstituted linear C1-C4, in particular C1-C2, alkyl radical, in particular ethyl; S represents a monosaccharide as previously described; especially D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and especially D-xylose; X represents a group chosen from -CO-, -CH (OH) -, -CH (NH 2) -, and preferentially a group -CH (OH) -.  Salts acceptable for non-therapeutic use of the compounds described in the present invention include conventional non-toxic salts of said compounds such as those formed from organic or inorganic acids.  By way of example, mention may be made of the salts of mineral acids, such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and boric acid.  There may also be mentioned organic acid salts, which may include one or more carboxylic acid, sulfonic acid, or phosphonic acid groups.  It may be linear, branched or cyclic aliphatic acids or aromatic acids.  These acids may furthermore comprise one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups.  These include propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid.  When the compound of formula (I) has an acid group, the neutralization of the acid group (s) can be carried out with a mineral base, such as LiOH, NaOH, KOH, Ca (OH) 2, NH 4 OH, Mg (OH) 2 or Zn (OH) 2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine.  This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; there may be mentioned amino-2-methyl-2-propanol, triamine triethanolamine, dimethylamino-2-propanol, 2-amino-2- (hydroxymethyl) -1,3-propanediol.  Mention may also be made of lysine or 3- (dimethylamino) propylamine.  Acceptable solvates for the compounds described in the present invention include conventional solvates such as those formed in the last step of preparing said compounds due to the presence of solvents.  By way of example, mention may be made of solvates due to the presence of water or of linear or branched alcohols, such as ethanol or isopropanol.  Among the C-glycoside derivatives of formula (I), used according to the invention, the following are particularly considered:  C- (3-D-xylopyranoside-n-propan-2-one; 2.  C-α-D-xylopyranoside-n-propan-2-one; 3.  1- [2- (3-Hydroxypropylamino) propyl] -C- (3-D-xylopyranose);  1- [2- (3-hydroxypropylamino) propyl] -C-α-D-xylopyranose; 5.  C- (3-D-xylopyranoside-2-hydroxypropane;  C-α-D-xylopyranoside-2-hydroxypropane; 7.  C- (3-D-xylopyranoside-2-amino-propane; 8.  C-α-D-xylopyranoside-2-aminopropane; 9.  C- (3-D-xylopyranoside-2-phenylamino-propane; 10.  C-α-D-xylopyrano-2-phenylamino-propane; 11.  3-methyl-4- (C- (3-D-xylopyranoside) -butyric acid ethyl ester;  3-methyl-4- (C-α-D-xylopyranoside) -butyric acid ethyl ester; 13.  6- (C- (3-D-xylopyranoside) -5-keto hexanoic acid;  6- (C-α-D-xylopyranoside) -5-keto hexanoic acid; 15.  6- (C- (3-D-xylopyranoside) -5-hydroxy-hexanoic acid; 16.  6- (C-α-D-xylopyranoside) -5-hydroxy-hexanoic acid; 17.  6- (C- (3-D-xylopyranoside) -5-aminohexanoic acid;  6- (C-α-D-xylopyranoside) -5-aminohexanoic acid; 19.  6- (C- (3-D-xylopyranoside) -5-phenylaminohexanoic acid;  6- (C-α-D-xylopyranoside) -5-phenylamino-hexanoic acid; 30 21.  1- (C- (3-D-xylopyranoside) -hexane-2,6-diol;  1- (C-α-D-xylopyranoside) -hexane-2,6-diol; 2903009 17 23.  5- (C- (3-D-xylopyranoside) -4-keto-pentanoic acid;  5- (C-α-D-xylopyranoside) -4-keto-pentanoic acid; 25.  5- (C- (3-D-xylopyranoside) -4-hydroxy-pentanoic acid;  5- (C-α-D-xylopyranoside) -4-hydroxy-pentanoic acid; 5 27.  5- (C- (3-D-xylopyranoside) -4-amino-pentanoic acid; 28.  5- (C-α-D-xylopyranoside) -4-amino-pentanoic acid; 29.  5- (C- (3-D-xylopyranoside) -4-phenylaminopentanoic acid;  5- (C-α-D-xylopyranoside) -4-phenylaminopentanoic acid; 31.  1- (C-13-D-xylopyranoside) -pentane-2,5-diol; 10 32.  1- (C-α-D-xylopyranoside) -pentane-2,5-diol; 33.  1- (C- (3-D-fucopyranoside) propan-2-one;  1- (C-α-D-fucopyranoside) -propan-2-one; 35.  1- (C- (3-L-fucopyranoside) propan-2-one;  1- (L-α-L-fucopyrano if) -propan-2-one; 37.  1- (C- (3-D-fucopyranoside) -2-hydroxypropane;  1- (C-α-D-fucopyranoside) -2-hydroxypropane; 39.  1- (C-L-fucopyranoside) -2-hydroxypropane; 40.  1- (C-α-L-fucopyranoside) -2-hydroxypropane; 41.  1- (C- (3-D-fucopyranoside) -2-amino-propane; 42.  1- (C-α-D-fucopyranoside) -2-amino-propane; 43.  1- (C- (3-L-fucopyranoside) -2-amino-propane;  1- (C-α-L-fucopyranoside) -2-amino-propane; 45.  1- (C- (3-D-fucopyranoside) -2-phenylaminopropane;  1- (C-α-D-fucopyranoside) -2-phenylamino propane; 47.  1- (C-13-L-fucopyranoside) -2-phenylamino propane; 48.  1- (C-α-L-fucopyranoside) -2-phenylamino propane; 49.  3-methyl-4- (C-β-D-fucopyranoside) -butyric acid ethyl ester; 50.  3-methyl-4- (C-α-D-fucopyranoside) -butyric acid ethyl ester; 51.  3-methyl-4- (C- (3-L-fucopyranoside) -butyric acid ethyl ester;  3-methyl-4- (C-α-L-fucopyranoside) -butyric acid ethyl ester; 2903009 18 53.  6- (C- (3-D-fucopyranoside) -5-keto hexanoic acid;  6- (C-α-D-fucopyranoside) -5-keto hexanoic acid; 55.  6- (C-13-L-fucopyranoside) -5-keto hexanoic acid; 56.  6- (C-α-L-fucopyranoside) -5-keto hexanoic acid; 5 57.  6- (C- (3-D-fucopyranoside) -5-hydroxy-hexanoic acid;  6- (C-α-D-fucopyranoside) -5-hydroxy-hexanoic acid; 59.  6- (C- (3-L-fucopyranoside) -5-hydroxy-hexanoic acid;  6- (C-α-L-fucopyranoside) -5-hydroxy-hexanoic acid; 61.  6- (C- (3-D-fucopyranoside) -5-aminohexanoic acid;  6- (C-α-D-fucopyranoside) -5-aminohexanoic acid; 63.  6- (C- (3-L-fucopyranoside) -5-aminohexanoic acid, 64.  6- (C-α-L-fucopyranoside) -5-aminohexanoic acid; 65.  1- (C- (3-D-fucopyranoside) -hexane-2,6-diol; 66.  1- (C-α-D-fucopyranoside) -hexane-2,6-diol; 67.  1- (C- (3-L-fucopyranoside) -hexane-2,6-diol;  1- (C-α-L-fucopyranoside) -hexane-2,6-diol; 69.  5- (C- (3-D-fucopyranoside) -4-keto-pentanoic acid; 70.  5- (C-α-D-fucopyranoside) -4-keto-pentanoic acid; 71.  5- (C- (3-L-fucopyranoside) -hexane-2,6-diol) -4-keto-pentanoic acid; 20 72.  5- (C-α-L-fucopyranoside) -hexane-2,6-diol) -4-keto-pentanoic acid; 73.  5- (C- (3-D-fucopyranoside) -4-hydroxy-pentanoic acid;  5- (C-α-D-fucopyranoside) -4-hydroxy-pentanoic acid; 75.  5- (C- (3-L-fucopyranoside) -4-hydroxy-pentanoic acid; 76.  5- (C-α-L-fucopyranoside) -4-hydroxy-pentanoic acid; 25 77.  5- (C-P-D-fucopyranoside) -4-amino-pentanoic acid; 78.  5- (C-α-D-fucopyranoside) -4-amino-pentanoic acid 79.  5- (C- (3-L-fucopyranoside) -4-amino-pentanoic acid;  5- (C-α-L-fucopyranoside) -4-amino-pentanoic acid; 81.  1- (C- (3-D-fucopyranoside) -pentane-2,5-diol; 82.  1- (C-α-D-fucopyranoside) -pentane-2,5-diol; 2903009 19 83.  1- (C- (3-L-fucopyranoside) -pentane-2,5-diol;  1- (C-α-L-fucopyranoside) -pentane-2,5-diol; 85.  1- (C-D-glucopyranosyl) -2-hydroxypropane; 86.  1- (C-α-D-glucopyranosyl) -2-hydroxypropane; 5 87.  1- (C-D-glucopyranosyl) -2-amino-propane; 88.  1- (C-α-D-glucopyranosyl) -2-amino-propane; 89.  1- (C- (3-D-glucopyranosyl) -2-phenylaminopropane;  1- (C-α-D-glucopyranosyl) -2-phenylamino propane; 91.  3-methyl-4- (C- (3-D-glucopyranosyl) -butyric acid ethyl ester;  3-methyl-4- (C-α-D-glucopyranosyl) -butyric acid ethyl ester; 93.  6- (C- (3-D-glucopyranosyl) -5-keto hexanoic acid;  6- (C-α-D-glucopyranosyl) -5-keto hexanoic acid; 95.  6- (C- (3-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 96.  6- (C-α-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 15 97.  6- (C -3-D-glucopyranosyl) -5-aminohexanoic acid; 98.  6- (C-α-D-glucopyranosyl) -5-aminohexanoic acid; 99.  6- (C- (3-D-glucopyranosyl) -5-phenylamino-hexanoic acid;  6- (C-α-D-glucopyranosyl) -5-phenylamino-hexanoic acid; 101.  1- (C- (3-D-glucopyranosyl) hexane-2,6-diol; 102.  1- (C-α-D-glucopyranosyl) hexane-2,6-diol; 103.  6- (C- (3-D-glucopyranosyl) -5-keto-pentanoic acid;  6- (C-α-D-glucopyranosyl) -5-keto-pentanoic acid; 105.  6- (C- (3-D-glucopyranosyl) -5-hydroxy-pentanoic acid;  6- (C-α-D-glucopyranosyl) -5-hydroxy-pentanoic acid; 25 107.  6- (C- (3-D-glucopyranosyl) -5-amino-pentanoic acid;  6- (C-α-D-glucopyranosyl) -5-hydroxy-pentanoic acid; 109.  6- (C- (3-D-glucopyranosyl) -5-phenylaminopentanoic acid;  6- (C-α-D-glucopyranosyl) -5-phenylaminopentanoic acid; 111.  1- (C-β-D-glucopyranosyl) -pentane-2,5-diol; 30 112.  1- (C-α-D-glucopyranosyl) -pentane-2,5-diol; 2903009 20 113.  1- (C-13-D-galactopyranosyl) -2-hydroxypropane; 114.  1- (C-α-D-galactopyranosyl) -2-hydroxypropane; 115.  1- (C-D-galactopyranosyl) -2-amino-propane; 116.  1- (C-α-D-galactopyranosyl) -2-amino-propane; 5 117.  1- (C- (3-D-galactopyranosyl) -2-phenylaminopropane;  1- (Ca-D-galactopyrano-syl) -2-phenylamino-propane; 119.  3-methyl-4 - ((3-D-galactopyranosyl) -butyric acid ethyl ester;  3-methyl-4- (α-D-galactopyranosyl) -butyric acid ethyl ester; 121.  6- (C- (3-D-galactopyranosyl) -5-keto hexanoic acid; 122.  6- (C-α-D-galactopyranosyl) -5-keto hexanoic acid; 123.  6- (C- (3-D-galactopyranosyl) -5-hydroxy-hexanoic acid;  6- (C-α-D-galactopyranosyl) -5-hydroxy-hexanoic acid; 125.  6- (C- (3-D-galactopyranosyl) -5-aminohexanoic acid;  6- (C-α-D-galactopyranosyl) -5-aminohexanoic acid; 15 127.  6- (C- (3-D-galactopyranosyl) -5-phenylamino-hexanoic acid; 128.  6- (C-α-D-galactopyranosyl) -5-phenylamino-hexanoic acid; 129.  1- (C- (3-D-galactopyranosyl) hexane-2,6-diol;  1- (C-α-D-galactopyranosyl) hexane-2,6-diol; 131.  6- (C- (3-D-galactopyranosyl) -5-keto-pentanoic acid; 132.  6- (C-α-D-galactopyranosyl) -5-keto-pentanoic acid; 133.  6- (C- (3-D-galactopyranosyl) -5-hydroxy-pentanoic acid; 134.  acid

  6- (C-α-D-galactopyranosyl) -5-hydroxy-pentanoic; 135. 6- (C-13-D-galactopyranosyl) -5-amino-pentanoic acid; 136. 6- (C-α-D-galactopyranosyl) -5-amino-pentanoic acid; 137. 6- (C- (3-D-galactopyranosyl) -5-phenylaminopentanoic acid; 138. 6- (CaD-galactopyranosyl) -5-phenylaminopentanoic acid; 139. 1- (C-D-) galactopyranosyl) -pentane-2,6-diol; 140. 1 - (CaD-galactopyranosyl) -pentane-2,6-diol; 1- (1- (C- (3-D-fucofuranosyl) propan-2-one; 142. 1- (CaD-fucofuranosyl) -propan-2-one; 143. 1- (C- (3-L-fucofuranosyl) -propan-2-one; 144. 1. - (CaL-fucofuranosyl) propan-2-one; 145. 3 '- (acetamido-C- (3-D-glucopyranosyl) propan-2'-one; 146. 3' - (acetamido-CaD-glucopyranosyl) propan-2 ' 147. 1- (acetamido-C- (3-D-glucopyranosyl) -2-hydroxylpropane; 148. 1- (acetamido-C-β-D-glucopyranosyl) -2-amino-propane; 1- (acetamido-C- (3-D-glucopyranosyl) -2-phenylamino-propane; 150. 1 - (acetamido-CaD-glucopyranosyl) -2-phenylamino-propane; 151. ethyl ester of 3-methyl acid 4- (acetamido-C-13-D-glucopyranosyl) -butyric acid; 152. ethyl ester of 3-methyl-4- (acetamido-CaD-glucopyranosyl) butyri acid 153. 6- (acetamido-C-13-D-glucopyranosyl) -5-keto hexanoic acid; 154. 6- (acetamido-C-α-D-glucopyranosyl) -5-keto hexanoic acid; 155. 6- (acetamido-C-13-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 156. 6- (acetamido-C-α-D-glucopyranosyl) -5-hydroxy-hexanoic acid; 157. 6- (acetamido-C- (3-D-glucopyranosyl) -5-aminohexanoic acid; 158. 6- (acetamido-CaD-glucopyranosyl) -5-aminohexanoic acid; acetamido-C- (3-D-glucopyranosyl) -5-phenylamino-hexanoic acid, 160. 6- (acetamido-CaD-glucopyranosyl) -5-phenylamino-hexanoic acid, 161. 1- (acetamido-C- (3-D) -glucopyranosyl) -hexane-2,6-diol; 162. 1 - (acetamido-CaD-glucopyranosyl) -hexane-2,6-diol; 163. 6- (acetamido-C- (3-D-glucopyranosyl) acid) -5-keto-pentanoic acid, 164. 6- (acetamido-CaD-glucopyranosyl) -5-keto-pentanoic acid, 165. 6- (acetamido-C- (3-D-glucopyranosyl) -5-hydroxy-pentanoic acid; 166. 6- (acetamido-CaD-glucopyranosyl) -5-hydroxy-pentanoic acid, 167. 6- (acetamido-C- (3-D-glucopyranosyl) -5-aminopentanoic acid, 168. 6- ( acetamido-CaD-glucopyranosyl) -5-aminopentanoic acid, 169. 6- (acetamido-C- (3-D-glucopyranosyl) -5-phenylaminopentanoic acid, 170. 6- (acetamido-CaD-glucopyranosyl) acid - 5-phenylaminopentanoic; 1- (acetamido-C-D-glucopyranosyl) -pentane-2,5-diol; 172. 1- (Acetamido-C-α-D-glucopyranosyl) -pentane-2,5-diol.

By way of non-limiting illustration of the C-glycoside derivatives which are more particularly suitable for the invention, mention may be made especially of the following derivatives: C- (3-D-xylopyranoside-n-propan-2-one, 5 CaD-xylopyranoside-n-propan-2-one, C- (3-D-xylopyranoside-2-hydroxy-propane, CaD-xylopyranoside-2-hydroxy-propane, 1- (C- (3-D- fucopyranoside) -propan-2-one, 1- (CaD-fucopyranoside) -propan-2-one, 1- (C- (3-L-fucopyranoside) -propan-2-one, 1- (CaL -fucopyranoside) -propan-2-one, 1- (C- (3-D-fucopyranoside) -2-hydroxypropane, 1- (CaD-fucopyranoside) -2-hydroxypropane, 1- (C (1- (3-L-fucopyranoside) -2-hydroxy-propane, 1- (CaL-fucopyranoside) -2-hydroxy-propane, 1- (C-13-D-glucopyranosyl) -2-hydroxylpropane, 1- (CaD-glucopyranosyl) -2-hydroxylpropane, 1- (C-13-D-galactopyranosyl) -2-hydroxylpropane, 1- (CaD-galactopyranosyl) -2-hydroxylpropane, 1- (C-13-D-fucofuranosyl) -propan-2-one, 1- (CaD-fucofuranosyl) -propan-2-one 1- (C- (3-L-fucofuranosyl) -propan-2-one, 1- (CaL-fucofuranosyl) -propan-2-one, C- (3-D-maltopyranoside-n-propane- 2-one, Ca-maltopyranoside-n-propan-2-one C- (3-D-maltopyranoside-2-hydroxy-propane, CaD-maltopyranoside-2-hydroxy-propane, their isomers and mixtures thereof .

According to one embodiment, C- (3-D-xylopyranoside-2-hydroxy-propane or CaD-xylopyranoside-2-hydroxy-propane, and more preferably CpD-xylopyranoside-2-hydroxypropane, may advantageously used for the preparation of a composition according to the invention According to one particular embodiment, the C-glycoside derivative may be CaD-xylopyranoside-2-hydroxy-propane in the form of a solution of 30% by weight of active material in a water / propylene glycol mixture (60/40% by weight), such as the product manufactured by Chimex under the trade name MEXORYL SBB.Of course, according to the invention, a C-glycoside derivative formula (I) may be used alone or in admixture with other C-glycoside derivatives and in any proportion.A C-glycoside derivative suitable for the invention may in particular be obtained by the synthesis method described in US Pat. WO 02/051828. The amount of derivative C- The glycoside to be used in a composition according to the invention depends on the desired cosmetic or therapeutic effect, and can therefore vary to a large extent. Those skilled in the art can easily, on the basis of their general knowledge, determine the appropriate quantities. A composition according to the invention may comprise a C-glycoside derivative in a proportion of about 0.0001% to about 25% by weight of active material relative to the total weight of the composition, and in particular of about 0.001% to about 10% by weight of active material, and more particularly from about 0.05% to about 5% by weight of active C-glycoside derivative relative to the total weight of the composition.

For use in peeling, the same levels can be provided in the corresponding compositions. Larger levels can also be used to further improve the desired desquamating effect and / or to reduce the desquamating agent content in the combination according to the invention.

The mass ratio between the desquamating agent and the C-glycoside derivative may vary depending on the galenic formulations and / or the intended applications.

The weight ratio may especially range from 0.0004 to 900, or even from 0.004 to 600, preferably from 0.01 to 300, and even more preferably from 0.01 to 150, or even from 0.01 to 100. In particular in anti-aging compositions, the mass ratio between the desquamating agent and the C-glycoside derivative can especially range from 0.01 to 100, preferably from 0.01 to 60, more preferably from 0.01 to at 30, even more preferably from 0.01 to 10, from 0.01 to 5, or even from 0.02 to 2%. In peeling compositions, the mass ratio between the desquamating agent and the C-glycoside derivative may especially range from 1 to 300, preferably from 2 to 150 and even more preferably from 2 to 100, or even from 2 to 50. ADDITIONAL AGENT The composition according to the present invention may further comprise at least one additional cosmetic and / or dermatological agent for improving the appearance and / or comfort of the skin and / or scalp. This additional agent may especially be an anti-aging and / or anti-wrinkle agent. The anti-aging and / or anti-wrinkle agent may especially be chosen from: an anti-glycation agent, such as a blueberry extract (Vaccinium angusfifollium), for example that sold under the name BLUEBERRY HERBASOL EXTRACT PG "by COSMETOCHEM, a black tea extract such as Sederma's Kombuchka, or lipoic or thioctic acid such as Labochim's Nutralip; an inhibitor of NO-synthase, such as extracts of Gingko biloba, Vitis vinifera or Olea europaea; An agent acting on dermal or epidermal macromolecules and / or preventing their degradation, such as extracts of Centella asiatica, asiaticosides and derivatives; ascorbic acid and its derivatives; synthetic peptides such as iamin, biopeptide CL or palmitoyl pentapeptide marketed by SEDERMA under the trade name Matrixil; the malt extract marketed by the company COLETICA under the trade name Collalift; lycopene; the Saccharomyces cerevisiae extract available in particular from the company SILAB under the trade name Firmalift or from the company LSN under the name 2903009 25 commercial Cytovitin; or on the inhibition of the degradation of elastin, such as the peptide extract of seeds of Pisum sativum marketed by the company LSN under the trade name Parelastyl; the N-acylaminoamide compounds described in application WO 01/94381 such as {2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino} acetic acid, otherwise known as N- [N] acetyl, N '- (3-trifluoromethyl) phenyl valyl] glycine or N-acetyl-N- [3- (trifluoromethyl) phenyl] valylglycine or acetyl trifluoromethyl phenyl valylglycine, or an ester thereof with a C 1 -C 4 alcohol C6. ; an extract of rice peptides such as Pentapharm's Colhibin, the extract of the brown alga Padina pavonica marketed by the company Alban Müller under the trade name HSP3; an extract of Laminaria ochroleuca such as Laminaïne from Secma; the lupine extract marketed by SILAB under the tradename Structurine; the extract of beech buds Fagus sylvatica marketed by Gattefosse under the trade name Gatuline RC; a peptide extract of Voandzeia substerranea such as that marketed by Laboratoires Serobiologiques under the trade name Filladyn LS 9397; an agent modulating the differentiation or the proliferation of the cells, and in particular the differentiation of keratinocytes and / or the proliferation of fibroblasts or keratinocytes and, such as a soy extract (hydrolysed soy proteins) such as the RIDULISSE of SILAB, 1,3,5-trimethoxybenzene (phloroglucinol: a myorelaxing and / or dermodecontracting agent, such as magnesium gluconate, manganese gluconate and other salts, alverine citrate and its salts, glycine, an extract of Iris pallida, a hexapeptide (Argériline R from Lipotec) or sapogenins such as Wild yam and carbonyl amines described in application EP1484052, and adenosine, an agent having a particular role of dermocontractant.These additional anti-aging agents are generally present in the cosmetic compositions at contents ranging from 0.01% to 20% by weight relative to the total weight of the composition, preferably from 0.01% to 10% by weight relative to total amount of the composition and even more preferably from 0.01 to 1% by weight relative to the total weight of the composition.

The invention therefore also relates to a composition comprising: at least one C-glycoside derivative, at least one desquamating agent chosen from n-octanoyl-5-salicylic acid, (N-2-hydroxyethylpiperazine-N-2- acid; ethane sulfonic acid (HEPES), an EDTA derivative and mixtures thereof; and at least one additional anti-aging agent, and preferably at least two anti-aging agents selected from adenosine, a malt extract, an extract of padina pavonica, a soy extract, an extract of wild yam, and their mixtures.

The compositions according to the invention comprise a physiologically acceptable medium. By acceptable physiological medium is meant a medium compatible with the materials and / or the keratinous fibers of human beings, such as, for example, without limitation, the skin, the mucous membranes, the nails, the scalp and / or the hair. This physiologically acceptable medium comprises water, optionally mixed or not with one or more organic solvents such as C 1 -C 8 alcohols, in particular ethanol, isopropanol, tert-butanol, n-butanol, polyols such as glycerin, propylene glycol, butylene glycol and polyol ethers.

The compositions according to the invention may be a cosmetic or dermatological composition and may therefore comprise a cosmetically or pharmaceutically acceptable medium. The composition may also comprise a fatty phase, which may comprise oils, gums, waxes usually used in the field of application under consideration. As oils or waxes that can be used in the invention, mention may be made of mineral oils (vaseline oil), vegetable oils (liquid fraction of shea butter, sunflower oil, apricot oil, rice bran ...) , animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes (cyclomethicone, dimethicone) and fluorinated oils (perfluoropolyethers), bees waxes, carnauba waxes, or paraffin waxes, shea butter, hydrogenated jojoba oil. To these oils can be added fatty alcohols (cetyl, stearyl, ...) and fatty acids (stearic acid, ....).

When the composition is an emulsion, the proportion of the fatty phase may range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition. The oils, the waxes, the emulsifiers and the coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics field. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% by weight relative to the total weight of the composition. The emulsion may further contain lipid vesicles. When the composition is an oily solution or gel, the fatty phase may represent more than 90% of the total weight of the composition. The composition may also contain adjuvants which are customary in the field in question, such as surfactants, emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters odor absorbers and dyestuffs, other cosmetic or pharmaceutical active agents. The amounts of these various adjuvants are those conventionally used in the cosmetics field, and for example from 0.01% to 10% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid spherules.

Suitable surfactants which may be used include, for example, glycerol stearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / glycol stearate sold under the name Tefose® 63 by the company Gattefosse; PEG stearate derivatives, sugar derivatives. As hydrophilic gelling agents that can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays. and lipophilic gelling agents include modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose, polyethylene. The composition may be in any conceivable galenic form.

In particular, the composition may have the form of an aqueous, alcoholic, hydroalcoholic or oily solution; a dispersion of the lotion or serum type; a water-in-oil, oil-in-water or multiple emulsion; a suspension; microcapsules or microparticles; vesicular dispersions of ionic and / or nonionic type; an aqueous, oily or serum lotion; a foam, a solid preparation for example stick; an aerosol composition also comprising a propellant under pressure or in the form of a patch. The composition according to the invention may be in the form of a composition for hair care, in particular a shampoo, a setting lotion, a treatment lotion, a cream or a styling gel, a dyeing composition, in particular oxidation, restructuring lotions for the hair, a composition of permanent (including a composition for the first time of a perm), a lotion or a fall protection gel, a pest control shampoo. It may also be in the form of a cleaning, protective, treatment or care composition for the face, the hands, the feet, the large anatomical folds or the body (for example day, night cream, make-up remover, sunscreen composition, body protection or skincare milk, after-sun milks, lotion, gel or mousse for skin care, such as cleaning lotion, artificial tanning composition) ; a body or facial makeup composition such as a foundation; a bath composition; a deodorant composition comprising, for example, a bactericidal agent; aftershave composition; an epilatory composition; a composition against insect bites; an anti-pain composition; a composition for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens, severe pruritus.

When the composition according to the invention is intended for use as a peel, it may also be in any of the galenic forms mentioned above provided that it is easily removed by rinsing, and in particular in the form of an aqueous gel. of aqueous or hydroalcoholic solution. It can be applied by any means allowing a uniform distribution and especially using a cotton, a rod, a brush, a gauze, a spatula or a buffer, or by spraying, and can be removed by rinsing with water or a mild detergent. According to a preferred embodiment of the invention, the composition for the chemical peel contains a continuous aqueous phase. The present invention also relates to a care composition of the skin and / or scalp, characterized in that the desquamating agent is selected from 5 beta-hydroxy acids, such as n-octanoyl 5-salicylic acid; urea and its derivatives; glycolic, citric, lactic, tartaric, malic or mandelic acids; (N-2-hydroxyethylpiperazine-N-2-ethane) sulfonic acid (HEPES); Saphora japonica extract; honey ; N-acetyl glucosamine and 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine), and laminar extracts such as laminaria saccharina and laminaria ochrolenca. The present invention finally relates to a peeling composition characterized in that the desquamating agent is present in a content greater than 20% by weight, for example ranging from 21% by weight to 70% by weight, in particular from 21 to 50% and even more preferably from 21 to 30% by weight relative to the total weight of the composition. The following examples illustrate the present invention. EXAMPLES Example 1: Evaluation on reconstructed skin of the desquamating effect of a mixture between a desquamating agent and a C-glycoside derivative The test uses a reconstructed skin model: it consists of evaluating by counting under the microscope the number of corneocytes released. after application of the desquamating product or the desquamating mixture to be tested.

After culturing the reconstructed skin models, the test products are applied topically at different concentrations ranging from 0.01 to 50% to evaluate a dose effect. The products to be tested are: glycolic acid at concentrations ranging from 1 to 70% by weight of active ingredient; C- (3-D-xylopyranoside-2-hydroxypropane in solution at 30% by weight in a water / propylene glycol 60/40 mixture used at concentrations ranging from 0.01 to 10% by weight of active ingredient, the mixture of 5-n-octanoylsalicylic acid and C- (3-D-xylopyranoside-2-hydroxypropane in solution at 30% by weight in a water / propylene glycol 60/40 mixture. Negative is a volume equivalent of MilliQ water The positive control is a solution of glycolic acid at 30% Each condition is treated in triplicate.

Once the action time has elapsed (10 minutes), the corneocytes released, following the treatment, are counted on glass slides. The following formulations are prepared according to conventional methods of the art. EXAMPLE 2 Lotion Chemical Name% by weight Glycolic Acid 10 Glycerin 3 CRD-xylopyranoside-2-hydroxy-1.5% propane 30% by weight of material (MA) active in a mixture of water / 1,2-propanediol 60/40 ethyl alcohol 96 degrees non-denatured Demineralized sterilized water QsplOO MA: active ingredient Example 3: Oil-in-water cream Phase Chemical name% weight A Preservative qs Disodium salt of ethylene di- 0.15 amine tetracetic acid, 2 H2O 15 2903009 (N-2-hydroxyethylpiperazine-N-0.25 2-ethane) sulfonic acid (HEPES) Glycerin 3 C- (3-D-xylopyranoside-2-hydroxypropane at 30% by weight of material 10% (MA ) active in a mixture of water / 1,2-propanediol 60/40 Demineralized water, sterilized 55,22 Mixture of glyceryl mono-stearate, polyethylene glycol stearate (100 0,3 0E) (50/50) B Pure cetyl alcohol, d natural origin 0.4 Preservative qs C N-octanoyl-5 salicylic acid 1 Isopropyl N-lauroylsarcosinate 10 Acrylic acid copolymer D acryli 0.5 stearyl methacrylate polymerized in a mixture of ethyl acetate / cyclohexane Cyclohexadimethylsiloxane (viscosity: 5 8 cSt) Demineralized sterilized water 10 E 96 degree undenatured ethyl alcohol 5 Acrylamide / acrylamido copolymer 2- F sodium methyl propane sulfonate in 1 inverse emulsion at 40% in isoparaffin / water H 99% Tri-ethanolamine 1.03 Demineralized sterilized water 7 MA = active ingredient The cream is applied daily to the skin of the face and / or the neck. Pleasant compositions to be applied which have desquamating properties are obtained without, however, causing tingling, tugging or heating sensations in the user.

Claims (22)

  1. Cosmetic and / or dermatological composition comprising, in a physiologically acceptable medium: from 0.001 to 95% by weight relative to the total weight of the composition of at least one desquamating agent and at least one C-glycoside derivative.   The composition of claim 1, wherein the desquamating agent is selected from beta-hydroxy acids, such as n-octanoyl-5-salicylic acid; urea and its derivatives; glycolic, citric, lactic, tartaric, malic or mandelic acids; (N-2-hydroxyethylpiperazine-N-2-ethane) sulfonic acid; Saphora japonica extract; honey ; N-acetyl glucosamine; 2-oxothiazolidine-4-carboxylic acid derivatives and mixtures thereof.   3. Composition according to the preceding claim, wherein the desquamating agent is chosen from glycolic acid, n-octanoyl-5-salicylic acid, (N-2-hydroxyethylpiperazine-N-2-ethane) sulfonic acid, 2-oxothiazolidine-4-carboxylic acid derivatives and mixtures thereof.   4. Composition according to any one of the preceding claims, characterized in that it comprises desquamating agent in a content ranging from 0.001 to 95% by weight relative to the total weight of the composition, in particular from 0, From 1 to 30% by weight relative to the total weight of the composition, preferably from 0.01 to 10% by weight relative to the total weight of the composition.   5. Composition according to any one of the preceding claims, in which the C-glycoside derivative has the following general formula (I): ## STR2 ## in which: R represents: a linear alkyl radical saturated with C1 to C20, in particular C1 to C10, unsaturated C 2 to C 20, in particular C 2 to C 10, or a branched or cyclic alkyl radical, saturated or unsaturated, C 3 to C 20, in particular C 3 to C 10; A linear hydrofluoro- or perfluoroalkyl radical, linear saturated with C 1 to C 20, in particular C 1 to C 10, or unsaturated C 2 to C 20, in particular C 2 to C 10, or branched or cyclic, saturated or unsaturated, C 3 to C C20, in particular C3 to C10, the hydrocarbon chain constituting said radicals being able, if appropriate, to be interrupted by 1, 2, 3 or more heteroatoms chosen from: oxygen, - sulfur, - nitrogen, and - a silicon, and possibly being substituted by at least one selected radical among: - -OR4, -SR4, -NR4R5, - COOR4, -CONHR4, - CN, a halogen atom, - a hydrofluoro- or perfluoro-C1-C6 alkyl radical, and / or a C3 cycloalkyl radical; at C8, with R4 and R5 being able to represent, independently of one another, a hydrogen atom, or an alkyl, perfluoroalkyl or linear hydrofluoroalkyl radical, saturated with C1 to C30, in particular with C1 to C12, or unsaturated with C2 to C30, especially C2 to C12, or branched or cyclic, saturated or unsaturated, C3 to C30, especially C3 to C12; or a C6 to C10 aryl radical, X is a radical selected from the groupings: wherein R1, R2 and R3 represent, independently of one another, an atom of hydrogen, or a radical R, with R as defined above, and R '1 representing a hydrogen atom, a group OH or a radical R as defined above, R1 may also denote a C6 to C10 aryl radical, S represents a monosaccharide or a polysaccharide comprising up to 20 sugar units, in particular up to 6 sugar units, in pyranose and / or furanose form, and of L and / or D series, said mono- or polysaccharide possibly being substituted by a necessarily free hydroxyl group, and optionally one or more optionally protected amine function (s), and the S-CH 2 -X bond represents a C-anomeric bond, which may be a or 13, as well as their cosmetically acceptable salts, their solvates t such as hydrates and their isomers.   6. Composition according to the preceding claim, S represents a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose, D-maltose and especially D-xylose.   7. Composition according to the preceding claim, in which X represents a group chosen from -CO-, -CH (OH) -, -CH (NH 2) -, and preferably a group -CH (OH) -. 2903009 35   8. Composition according to the preceding claim, wherein R denotes a linear radical C1-C4, in particular C1-C3, optionally substituted with -OH, -COOH or ùCOOR "2, R" 2 being a saturated alkyl radical C1-C4, especially ethyl.   9. A composition according to any one of the preceding claims, wherein the C-glycoside derivative is selected from: C- (3-D-xylopyranoside-n-propan-2-one, CaD-xylopyranoside-n-propane -2-one, C- (3-D-xylopyranoside-2-hydroxy-propane, - CaD-xylopyranoside-2-hydroxy-propane, 1- (C-13-D-fucopyranoside) -propane-2 -one, 1- (CaD-fucopyranoside) -propan-2-one, 1- (C-13-L-fucopyranoside) -propan-2-one, 1- (CaL-fucopyranoside) -propane-2 -one, 1- (C- (3-D-fucopyranoside) -2-hydroxy-propane, 1- (CaD-fucopyranoside) -2-hydroxypropane, 1- (C- (3- L-fucopyranoside) -2-hydroxypropane, 1- (CaL-fucopyranoside) -2-hydroxypropane, 1- (C- (3-D-glucopyranosyl) -2-hydroxylpropane, Ca-glucopyranosyl) -2-hydroxyl-propane, 1- (C- (3-D-galactopyranosyl) -2-hydroxyl-propane, 1- (CaD-galactopyranosyl) -2-hydroxyl-propane - 1- ( CpD-fucofuranosyl) -propan-2-one, 1- (CaD-fucofuranosyl) -propan-2-one 1- (C-13-L-fucofuranosyl) propan-2-one one, 1- (CaL-fucofuranosyl) -propan-2-one, C- (3-D-maltopyranoside-n-propan-2-one, CaD-maltopyranoside-n-propan-2-one C- (3-D-maltopyranoside-2-hydroxy-propane, - CaD-maltopyranoside-2-hydroxy-propane, their isomers and mixtures thereof. 2903009 36   10. The composition as claimed in any one of the preceding claims, in which the C-glycoside derivative is chosen from C- (3-D-xylopyranoside-2-hydroxypropane and CaD-xylopyranoside-2-hydroxy-propane, and is more particularly C- (3-D-xylopyranoside-2-hydroxypropane.   11. Composition according to the preceding claim, in which R denotes a linear radical in C1-C4, in particular C1-C3, optionally substituted by -OH, -COOH or ùCOOR "2, R" 2 being a saturated alkyl radical C1-C4, especially ethyl.   12. A composition according to any one of the preceding claims, wherein the C-glycoside derivative is selected from: C- (3-D-xylopyranoside-n-propan-2-one, CaD-xylopyranoside-n-propane -2-one, C- (3-D-xylopyranoside-2-hydroxy-propane, CaD-xylopyranoside-2-hydroxy-propane, 1- (C-13-D-fucopyranoside) -propan-2-one 1- (Ca-Fucopyranoside) -propan-2-one, 1- (C- (3-L-fucopyranoside) -propan-2-one, 1- (CaL-fucopyranoside) -propane-2 -one, 1- (C-13-D-fucopyranoside) -2-hydroxy-propane, 1- (CaD-fucopyranoside) -2-hydroxy-propane, 1- (C- (3-L) 2-hydroxypropane, 1- (CaL-fucopyranoside) -2-hydroxy-propane, 1- (C- (3-D-Glucopyranosyl) -2-hydroxylpropane, 1- (CaD-fucopyranoside) 2-hydroxypropane, 1- (C- (3-D-galactopyranosyl) -2-hydroxylpropane, 1- (CaD-galactopyranosyl) -2-hydroxylpropane 1- C-13-D-fucofuranosyl) -propan-2-one, 1- (CaD-fucofuranosyl) -propan-2-one 1- (C- (3-L-fucofuranosyl) propan) e-2-one, 1- (CaL-fucofuranosyl) -propan-2-one, C- (3-D-maltopyranoside-n-propan-2-one), - CaD-maltopyranoside-n-propane- 2-one C- (3-D-maltopyranoside-2-hydroxy-propane, CaD-maltopyranoside-2-hydroxy-propane, their isomers and mixtures thereof.   A composition according to any one of the preceding claims wherein the C-glycoside derivative is selected from C- (3-D-xylopyranoside-2-hydroxypropane and CaD-xylopyranoside-2-hydroxypropane, and is more particularly C- (3-D-xylopyranoside-2-hydroxypropane.   14. Cosmetic use of at least one desquamating agent in combination with at least one C-glycoside derivative or of a composition as defined in any one of Claims 1 to 13, for promoting desquamation of the skin and / or or scalp and / or stimulate epidermal renewal.   15. Use according to claim 14, characterized in that said combination or composition is intended to prevent, attenuate and / or fight against the signs of skin aging, improve the appearance and / or texture of the skin and / or leather hair, and in particular to improve the radiance and homogeneity of the complexion and / or smooth the skin, reduce surface irregularities and cutaneous microrelief, promote the cleaning action and the elimination of dead cells on the surface of the body to promote the elimination of dandruff, to fight against the imperfections of oily skin, to improve the hold of the make-up and / or to improve the treatment result of the skin with stratum corneum dyes such as dihydroxyacetone.   16. Use of at least one desquamating agent in combination with at least one C-glycoside derivative or a composition according to any one of claims 1 to 13 for the preparation of a composition intended to treat certain pathologies of the skin related to abnormal desquamation, such as xerosis, ichthyosis, psoriasis, atopic dermatitis.   17. Cosmetic treatment method for the non-therapeutic care of the skin and / or the scalp, characterized in that it comprises the simultaneous or sequential application to the skin, via at least one composition, of at least a C-glycoside derivative and at least one desquamating agent. 30   18. The method of claim 17, comprising at least one step of applying to the skin and / or the scalp a cosmetic composition as defined in any one of claims 1 to 13. 2903009 38   19. Method according to one of claims 17 or 18, characterized in that it is a method for preventing, attenuating and / or fighting against the signs of skin aging, improve the appearance and / or texture of the skin and / or the scalp, and in particular to improve the radiance and homogeneity of the complexion and / or to smooth the skin, to reduce the surface irregularities and the skin microrelief, to promote the cleaning action and the elimination dead cells on the surface of the body, promote the elimination of dandruff, improve the makeup performance and / or improve the treatment result of the skin with stratum corneum dyes such as dihydroxyacetone.   20. A process according to any one of claims 17 to 19 wherein the C-glycoside derivative and the desquamating agent are packaged in two separate compositions.   21. A method of cosmetic treatment of visible and / or tactile irregularities of human skin, comprising the steps of: a) topically applying to the skin a composition according to any one of claims 1 to 13, b) leaving the composition in contact with the skin for a period of between 5 minutes and 6 hours, preferably between 5 minutes and 30 minutes, and c) remove the composition by rinsing. 20   22. Method according to claim 21, characterized in that it is intended to prevent, attenuate, and / or fight against the signs of skin aging, and in particular to reduce wrinkles and fine lines, and to improve the appearance and / or the texture of the skin, in particular to improve the homogeneity of the complexion and / or smooth the skin, and in particular to reduce actinic lentigo, or marks of acne or chickenpox, and / or to unclog the pores of the skin.